價格 | ¥1290 | ¥1930 | ¥2920 |
包裝 | 1mg | 2mg | 5mg |
最小起訂量 | 1mg |
發(fā)貨地 | 上海 |
更新日期 | 2024-12-12 |
中文名稱:化合物 DORA-22 | 英文名稱:DORA-22 |
CAS:1088991-95-0 | 品牌: TargetMol |
產(chǎn)地: 美國 | 保存條件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
純度規(guī)格: 97.67% | 產(chǎn)品類別: 抑制劑 |
貨號: T5500 |
名稱 | DORA-22 |
描述 | DORA-22 is a dual orexin receptor antagonist, improves mild stress-induced insomnia with minimal effect on memory |
動物實驗 | Animals were first trained to remember the location of a hidden platform (acquisition) in the Morris Water Maze and then administered DORA-22 (10, 30, or 100 mg/kg doses) or vehicle control.?Animals were then subjected to a rodent insomnia model involving two exposures to dirty cages over a 6-hr time period (at time points 0 and 3 hr), followed immediately by a probe trial in which memory of the water maze platform location was evaluated[1]. |
體內(nèi)活性 | DORA-22, a dual orexin receptor antagonist, improves mild stress-induced insomnia with minimal effect on memory.DORA-22 treatment improved the insomnia-related sleep disruption-wake was attenuated and NREM sleep was normalized.?REM sleep amounts were enhanced compared with vehicle treatment for one dose (30 mg/kg).?In the first hour of insomnia model exposure, DORA-22 promoted the number and average duration of NREM sleep spindles, which have been previously proposed to play a role in memory consolidation (all doses).?Water maze measures revealed probe trial performance improvement for select doses of DORA-22, including increased time spent in the platform quadrant (10 and 30 mg/kg) and time spent in platform location and number of platform crossings (10 mg/kg only).?In conclusion, DORA-22 treatment improved insomnia-related sleep disruption and memory consolidation deficits[1]. |
存儲條件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度 | DMSO : 10 mg/mL (23.56 mM) |
關(guān)鍵字 | DORA-22 | DORA 22 | DORA22 |
相關(guān)產(chǎn)品 | Orexin B, rat, mouse Acetate | L-368,899 hydrochloride | PF3274167 | ACT-462206 | TCS 1102 | OXA (17-33) acetate | YNT-185 | Filorexant | MK-3697 | Seltorexant | IPSU | EMPA |
相關(guān)庫 | 抑制劑庫 | 經(jīng)典已知活性庫 | 已知活性化合物庫 | 神經(jīng)信號分子庫 | NO PAINS 化合物庫 | GPCR靶點分子庫 | 膜蛋白靶向化合物庫 | 表型篩選靶點鑒定庫 |
成立日期 | 2013-04-18 (12年) | 注冊資本 | 566.265100萬人民幣 |
員工人數(shù) | 100-500人 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 天然產(chǎn)物,生化試劑,分子生物學(xué),分子砌塊,生物技術(shù)服務(wù) | 經(jīng)營模式 | 貿(mào)易,工廠,試劑,定制,服務(wù) |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
詢價 |
VIP3年
|
陜西締都新材料有限公司
|
2024-12-18 | |
詢價 |
VIP1年
|
青島愷潤生物醫(yī)藥科技有限公司
|
2024-11-02 | |
詢價 |
VIP5年
|
陜西締都醫(yī)藥化工有限公司
|
2024-12-18 |